Safety and Efficacy of ABT-510 in Subjects With Advanced Renal Cell Carcinoma
NCT00073125
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
103
Enrollment
INDUSTRY
Sponsor class
Conditions
Carcinoma, Renal Cell
Interventions
DRUG:
ABT-510/Thrombospondin-1 mimetic
Sponsor
Abbott